Les Meilleurs doctors pour votre Bilan oncologique pour les femmes - TOP 60 des médecins

Wolfgang Johannes Köstler est un spécialiste certifié en médecine interne, hématologie/oncologie et médecine des soins intensifs, spécialisé en hématologie et oncologie interne, médecine des soins intensifs. Il est l'un des spécialistes du cancer du sein et du sarcome les mieux classés et possède une vaste expérience dans ce domaine. Il est diplômé de l'Université médicale de Vienne et de l'Institut scientifique Weizmann. Il a également suivi une formation spéciale au Memorial Sloan-Kettering Cancer Center et au Royal Prince Alfred Hospital.

Professional Experience

Gayrettepe Florence Nigthingale Hospital

Medical Oncology Department

Besiktas/Istanbul/Turkey (ongoing)

Education:

He became Professor (22/April /2016)

Medical Oncology

Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)

Istanbul University Oncology Institue,

Department of Medical Oncology

Medical Oncology Fellowship (December 2001-December2004)

Istanbul University, Istanbul Medical Faculty

Hemodialysis Traning (May1996-January1997)

Istanbul University ,bCerrahpasa Medical Faculty

Internal Medicine Residency (November 1991-November 1996)

Istanbul University ,bCerrahpasa Medical Faculty

Ege University Medical Faculty (1985-1991)

Professional Experience

February 1999-November 2001

Metropolitan Florence Nigthingale Hospital

American Cancer Center, Gayrettepe/İstanbul

April1997- October 1998

Bayraktar Dialysis Center

Güngören/ Istanbul

Membership

Turkish Medical Oncology Association

ENET(European Neuroendocrine Tumour Society)

ESMO

ASCO

Le professeur Dan Grisaro est un éminent spécialiste israélien du diagnostic et du traitement des cancers gynécologiques, notamment des cancers de l'ovaire, de l'utérus et du col de l'utérus. Il a une expérience de médecin-chef, de chef de service et de conférencier dans divers centres médicaux et universités. Il a donné 39 présentations et est l'auteur de 83 articles scientifiques publiés. Il est membre de plusieurs sociétés professionnelles.

Radiologue. Hear de l'Institut de Radiologie Diagnostique et Interventionnelle

Education:

• Degree: Faculty of Medicine, Trakya University, 2009
• Medical Specialty: Internal Medicine, Bakırköy Dr. Sadi Konuk Training and Research Hospital, 2010-2014
• Specialist Doctor: Internal Medicine, Kanuni Sultan Süleyman Training and Research Hospital, 2014-2019
• Specialist Doctor: Internal Medicine, Turkish Hospital Internal Medicine Clinic, Qatar, 2019-2020
• Specialist Doctor: Internal Medicine, Istanbul Medipol University Hospital Mega Hospital Internal Medicine Department, 2020-2024
• Associate Professor Doctor: Internal Medicine, Istanbul Medipol University Medipol Acıbadem Regional Hospital, 2024-Present.

Roles in Projects:

Sub investigator (Assistant Researcher) in the SOUL Study: Cardiovascular Outcome Research of Semaglutide in Type 2 Diabetic Patients, approved by the Turkish Medicines and Medical Devices Agency on May 22, 2019.

Sub investigator (Assistant Researcher) in the international study “SCALE™ Insulin”: Efficacy and Safety of Liraglutide 3.0 mg in Overweight or Obese Patients with Type 2 Diabetes Treated with Basal Insulin (Study Code: NN8022-4272), conducted by Novo Nordisk A.Ş.

Subinvestigator (Assistant Researcher) in the international study NN5401-4266 StepByStep Intensification conducted by Novo Nordisk.

Assistant Researcher in the study "A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)" (2019-2020).

Assistant Researcher in the PIONEER 1 study: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Education 

2002 Haydarpaşa Numune Training and Research Hospital, Internal Medicine 

1990 Erciyes University, Faculty of Medicine 

Experience 

2019 - 2019 Okan University Hospital 

2018 - 2019 Ibn Sina Hospital 

2003 - 2018 Pendik State Hospital 

1997 - 2003 Haydarpasa Numune Hospital 

1990 - 1994 Erzincan State Hospital 

Istanbul Haydarpasa Numune Hospital 

Kartal Health Group Presidency 

Yıldırım Beyazıt Mother and Child Health Physician 

Education

• (2004 – 2011), Faculty of Medicine/ Inonu University/ Malatya, Turkiye
• (2011 – 2015), Department of Radiology/ Bagcilar Training and Research Hospital/ Istanbul, Turkiye

Career

• (2016 – 2020), Diagnostic and Interventional Radiologist/ Mus State Hospital/ Mus,Turkiye
• (2020 – 2022), Assistant Professor of Diagnostic and Interventional Radiology/ Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2023 – 2024), Associate Professor of Diagnostic and Interventional Radiology /Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2024 - Present), Associate Professor of Diagnostic and Interventional Radiology /Medipol University Hospital/ Istanbul, Turkiye

• 1989 - obtient son diplôme de médecine à l'Université hébraïque;
• 1995 - effectue son internat en médecine interne et gastroentérologie à l'hôpital universitaire Hadassah.
• 2001 - 2002 - formation auprès du professeur Scott Friedman dans le département des maladies du foie à la Sinai School of Medicine de New York.

Aujourd'hui, le professeur Rifaat Safadi est un éminent spécialiste du traitement des maladies du foie, membre du comité de développement du centre de transplantation de cellules somatiques et chef de l'unité des maladies du foie à Hadassah. Il est membre de plusieurs associations internationales sur le foie et a rédigé de nombreux articles dans sa spécialité. Le professeur Safadi fait partie du comité de rédaction de la revue médicale scientifique Clinical Science.

Rifaat Safadi a reçu de nombreux prix scientifiques. Il a notamment reçu plusieurs fois le prix Hadassah - pour son étude de la modulation immunitaire de la fibrose hépatique par l'ARNm. Pour ses réalisations dans le même domaine, le professeur a reçu le prix Sharon Donsky et l'Association israélienne de gastroentérologie et d'hépatologie.

Le Dr. est titulaire d'un diplôme de médecine de la faculté de médecine de l'université d'Uludağ, Bursa, Turquie (1983), d'une bourse post-doctorale en thermoradiothérapie de l'université Thomas Jefferson, Philadelphie, Pennsylvanie (1990-1994), et d'une résidence en radio-oncologie du Centre d'oncologie et de médecine nucléaire d'Istanbul, Turquie (1990). Il a également occupé les postes de professeur, président et coordinateur de l'accréditation de la faculté au Collège médical de l'Université Uludağ (1991-2005), professeur et directeur au Centre médical Anadolu (2004-2017), et directeur à l'Hôpital international Ceylan et à l'Hôpital Medicana Bursa (2017-aujourd'hui).